LP
MTNB icon

LMR Partners’s Matinas BioPharma MTNB Stock Holding History

LMR Partners’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,986
Closed -$104K – 1255
2021
Q1 		$104K Buy
+1,986
New +$133K ﹤0.01% 855
2018
Q3 		– Sell
-3,981
Closed -$86K – 451
2018
Q2 		$86K Buy
+3,981
New +$115K ﹤0.01% 450

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

LMR Partners's MTNB Position: Q2 2021 in Review

LMR Partners sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 1,986 shares — an estimated $104K sold.

LMR Partners first reported a position in MTNB in Q2 2018 and held it in 2 quarters. The position peaked at $104K in Q1 2021. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • LMR Partners reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • LMR Partners sold 1,986 Matinas BioPharma shares in Q2 2021, an estimated $104K.
  • LMR Partners first reported a position in Matinas BioPharma in Q2 2018 and held it in 2 quarters.
  • LMR Partners's Matinas BioPharma position peaked at $104K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on LMR Partners's 13F filing for Q2 2021, filed 16 Aug 2021.